Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia

A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia

Trial Details

NCT ID
NCT04534127
Phase
NA
Sponsor
Alpha Tau Medical LTD.
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Locations (sample)
  • Jerusalem, Israel|31.76904,35.21633

Key Eligibility Criteria

  • Subjects with histopathological confirmation of primary or secondary malignant cutaneous neoplastic lesions, or oral cavity mucosal tumors, or supe…
  • Subjects with a tumor size ≤ 7 centimeters in the longest diameter.
  • Targetable lesion must be technically amenable for complete coverage (including margins) by the DaRT seeds
  • Brachytherapy indication validated by a multidisciplinary team

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →